Peptidyl Arginine Deiminase 4: APromising Therapeutic Target in Rheumatoid Arthritis and Other Diseases
Main Article Content
Abstract
The present review offers comprehensive data on the roles of Peptidyl Arginine Deiminase 4 (PAD4) in various
diseases, including rheumatoid arthritis (RA). PAD4, an enzyme responsible for converting arginine to citrulline,
has been linked to the development of chronic inflammation. The current study is a narrative review to determine
whether PAD4 is a potential therapeutic target for RA and other illnesses. We searched PubMed and Google
Scholar for studies published before 2024. The potential therapeutic utility of PAD4 in various diseases such as
cancer, miscarriage, multiple sclerosis, retinopathy, and RA is emphasized in the article. This paper explores the
advancements in the development of small-molecule inhibitors and monoclonal antibodies targeting PAD4. It
stresses the importance of conducting additional research to resolve specificity, safety, and sustained effectiveness
concerns. The review emphasizes the need for a comprehensive approach to completely comprehend the varied
attributes and potential therapeutic applications of PAD4.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.